fexofenadine has been researched along with Acute Lung Injury in 1 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
Acute Lung Injury: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Liu, H | 1 |
| Tian, Y | 1 |
| Luo, Z | 1 |
| Ran, J | 1 |
| Miao, Z | 1 |
| Zhang, Q | 1 |
| Yin, G | 1 |
| Xie, Q | 1 |
1 other study available for fexofenadine and Acute Lung Injury
| Article | Year |
|---|---|
Fexofenadine protects against lipopolysaccharide-induced acute lung injury by targeting cytosolic phospholipase A2.
Topics: Acute Lung Injury; Animals; Cytokines; Lipopolysaccharides; Lung; Mice; Mice, Knockout; NF-kappa B; | 2023 |